Anti-Human IL1Beta Therapeutic Antibody (Canakinumab)
Recombinant monoclonal antibody to Human IL1 beta. Canakinumab (INN, trade name Ilaris, previously ACZ885) is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.
Canakinumab was for the treatment of rheumatoid arthritis. Canakinumab is as a possible treatment for chronic obstructive pulmonary disease, gout and coronary artery disease.
Canakinumab was for the treatment of rheumatoid arthritis. Canakinumab is as a possible treatment for chronic obstructive pulmonary disease, gout and coronary artery disease.
| Supplier | Creative Biolabs |
|---|---|
| Product # | TAB-021 |
| Pricing | Inquiry |
| Host | Human |
| Target | IL1 beta |
| Species Reactivity | Human |
| Type | IgG1 - kappa |
| Applications | Suitable for use in FC, IP, ELISA, Neut, FuncS, IF, IHC and most other immunological methods. |
| Storage | Store at -20°C. Avoid multiple freeze/thaw cycles. |